Effectiveness and Safety of Nedaplatin Combined with Chemotherapy for Advanced Non-small Cell Lung Cancer: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 GUO Wei , LI Jianhua , WANG Feng

Clinical Research Institute, Jiangsu Simcere Pharmaceutical R&D Co. Ltd., Nanjing 210042, China;

Corresponding author：

GUO Wei, Email: guowei@simcere.com

Keywords：

Nedaplatin; Cisplatin; Non-small cell lung cancer; Meta-analysis; Systematic review; Randomized controlled trial

DOI：

10.7507/1672-2531.20130011

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To evaluate the effectiveness and safety of nedaplatin combined with chemotherapy versus cisplatin combined with chemotherapy for advanced non-small cell lung cancer (NSCLC).
Methods 　The randomized controlled trials (RCTs) on nedaplatin combined with chemotherapy versus cisplatin combined with chemotherapy for advanced NSCLC were searched in The Cochrane Library, PubMed, EMbase, CBM, VIP and WanFang Data from the date of their establishment to January 2012. According to the inclusion and exclusion criteria, two reviewers independently screened the studies, extracted the data and assessed the quality. Then RevMan 5.0 software was used for meta-analysis.
Results 　A total of 15 RCTs involving 1 076 patients were included. The results of meta-analysis showed that, compared with the cisplatin combined with chemotherapy, nedaplatin combined with chemotherapy could reduce the risks of nausea and vomiting (RR=0.56, 95%CI 0.48 to 0.65, P lt;0.000 01), decrease the risk of renal function impairment (RR=0.47, 95%CI 0.30 to 0.74, P=0.001), but increase the risk of thrombocytopenia (RR=1.59, 95%CI 1.20 to 2.11, P=0.001). There were no significant differences between the two groups in objective response rate (ORR) (RR=1.09, 95%CI 0.92 to 1.29, P=0.03), leukopenia (RR=1.05, 95%CI 0.92 to 1.19, P=0.50), and hemoglobin reduction (RR=0.92, 95%CI 0.80 to 1.07, P=0.30).
Conclusion 　Compared with cisplatin combined with chemotherapy for advanced NSCLC patients, nedaplatin in combination with chemotherapy can significantly reduce the risks of nausea, vomiting and renal function impairment. Although the ORRs are similar in the two groups, nedaplatin combined with chemotherapy can cause a higher risk of thrombocytopenia. For the quality restriction and possible publication bias of the included studies, more high quality RCTs are required to further verify this conclusion.

Citation： GUO Wei,LI Jianhua,WANG Feng. Effectiveness and Safety of Nedaplatin Combined with Chemotherapy for Advanced Non-small Cell Lung Cancer: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2013, 13(1): 47-54. doi: 10.7507/1672-2531.20130011 Copy

1.	National Cancer Institute SEER data. Available from: http://seer.cancer.gov/statistics/.
2.	Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest, 2003 Jan; 123(1 Suppl): 226S-243S.
3.	Wheate NJ, Walker S, Craig GE, et al. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans, 2010, 39(35): 8113-8127.
4.	Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
5.	陈丽昆, 徐光川, 管忠震, 等. 奈达铂或顺铂联合紫杉醇治疗晚期非小细胞肺癌的随机对照研究. 中华肿瘤杂志, 2007, 29(6): 437-440.
6.	徐瑞华, 管忠震, 姜文奇等. 奈达铂治疗非小细胞肺癌的Ⅱ期临床研究报告. 癌症, 2002, 21 (12 ): 1354-1358.
7.	孙中义, 何执鼎. 国产奈达铂联合紫杉醇治疗晚期非小细胞肺癌. 中国癌症杂志, 2006, 16(8): 679-680.
8.	肖天林, 刘小红, 杨超. 奈达铂联合多西他赛治疗晚期非小细胞肺癌临床观察. 现代肿瘤医学, 2010, 18(1): 81-83.
9.	蔡友鹏, 许慎, 林淑君. 紫杉醇和顺铂与紫杉醇和奈达铂治疗晚期非小细胞肺癌的对比观察. 中华肿瘤杂志, 2010, 32(1): 74-75.
10.	张频, 冯奉仪, 吴令英, 等. 奈达铂治疗恶性肿瘤的临床研究. 中华肿瘤杂志, 2006, 28(3): 230-234.
11.	Furuse K, Fukuoka M, Asamoto H, et al. A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC). Gan To Kagaku Ryoho, 1992 Jul;19(7):1019-1026.
12.	佟仲生, 李淑芬, 汪旭, 等. 注射用奈达铂治疗头颈部鳞癌与食管癌及非小细胞肺癌Ⅱ期临床试验研究. 肿瘤防治杂志, 2005, 12(23): 1779-1784.
13.	洪燕, 孙书明, 储德节. 奈达铂联合长春瑞滨治疗晚期非小细胞肺癌的临床观察. 临床肿瘤学杂志, 2006, 11(5): 391-393.
14.	吕靖, 英焕春, 薛文. 奈达铂联合长春瑞滨治疗晚期非小细胞肺癌的临床观察. 中国医药导报, 2009, 6(7): 50-51.
15.	缪建华, 张迦维, 陈暑波. 奈达铂联合吉西他滨治疗晚期非小细胞肺癌的临床研究. 临床肿瘤学杂志, 2007, 12(4): 297-299.
16.	孙超, 时会云, 袁东朋. 紫杉醇联合NDP方案和联合DDP方案治疗非小细胞肺癌的临床疗效观察. 海南医学, 2010, 21(11): 28-30.
17.	李明毅, 梁颖, 黄河, 等. 紫杉醇联合不同铂类治疗晚期非小细胞肺癌临床研究. 疑难病杂志, 2009, 8(8): 465-467.
18.	刘军校, 刘世伟, 石婧. 长春瑞滨联合奈达铂治疗晚期非小细胞肺癌的临床观察. 中国医师杂志, 2010, 12(11): 1569-1570.
19.	李勇, 许凤, 陈石伟, 等. 奈达铂联合长春瑞滨治疗非小细胞肺癌的临床观察. 临床肿瘤学杂志, 2006, 11(7): 533-534,538.

1. National Cancer Institute SEER data. Available from: http://seer.cancer.gov/statistics/.
2. Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest, 2003 Jan; 123(1 Suppl): 226S-243S.
3. Wheate NJ, Walker S, Craig GE, et al. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans, 2010, 39(35): 8113-8127.
4. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
5. 陈丽昆, 徐光川, 管忠震, 等. 奈达铂或顺铂联合紫杉醇治疗晚期非小细胞肺癌的随机对照研究. 中华肿瘤杂志, 2007, 29(6): 437-440.
6. 徐瑞华, 管忠震, 姜文奇等. 奈达铂治疗非小细胞肺癌的Ⅱ期临床研究报告. 癌症, 2002, 21 (12 ): 1354-1358.
7. 孙中义, 何执鼎. 国产奈达铂联合紫杉醇治疗晚期非小细胞肺癌. 中国癌症杂志, 2006, 16(8): 679-680.
8. 肖天林, 刘小红, 杨超. 奈达铂联合多西他赛治疗晚期非小细胞肺癌临床观察. 现代肿瘤医学, 2010, 18(1): 81-83.
9. 蔡友鹏, 许慎, 林淑君. 紫杉醇和顺铂与紫杉醇和奈达铂治疗晚期非小细胞肺癌的对比观察. 中华肿瘤杂志, 2010, 32(1): 74-75.
10. 张频, 冯奉仪, 吴令英, 等. 奈达铂治疗恶性肿瘤的临床研究. 中华肿瘤杂志, 2006, 28(3): 230-234.
11. Furuse K, Fukuoka M, Asamoto H, et al. A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC). Gan To Kagaku Ryoho, 1992 Jul;19(7):1019-1026.
12. 佟仲生, 李淑芬, 汪旭, 等. 注射用奈达铂治疗头颈部鳞癌与食管癌及非小细胞肺癌Ⅱ期临床试验研究. 肿瘤防治杂志, 2005, 12(23): 1779-1784.
13. 洪燕, 孙书明, 储德节. 奈达铂联合长春瑞滨治疗晚期非小细胞肺癌的临床观察. 临床肿瘤学杂志, 2006, 11(5): 391-393.
14. 吕靖, 英焕春, 薛文. 奈达铂联合长春瑞滨治疗晚期非小细胞肺癌的临床观察. 中国医药导报, 2009, 6(7): 50-51.
15. 缪建华, 张迦维, 陈暑波. 奈达铂联合吉西他滨治疗晚期非小细胞肺癌的临床研究. 临床肿瘤学杂志, 2007, 12(4): 297-299.
16. 孙超, 时会云, 袁东朋. 紫杉醇联合NDP方案和联合DDP方案治疗非小细胞肺癌的临床疗效观察. 海南医学, 2010, 21(11): 28-30.
17. 李明毅, 梁颖, 黄河, 等. 紫杉醇联合不同铂类治疗晚期非小细胞肺癌临床研究. 疑难病杂志, 2009, 8(8): 465-467.
18. 刘军校, 刘世伟, 石婧. 长春瑞滨联合奈达铂治疗晚期非小细胞肺癌的临床观察. 中国医师杂志, 2010, 12(11): 1569-1570.
19. 李勇, 许凤, 陈石伟, 等. 奈达铂联合长春瑞滨治疗非小细胞肺癌的临床观察. 临床肿瘤学杂志, 2006, 11(7): 533-534,538.

Chinese Journal of Evidence-Based Medicine

Effectiveness and Safety of Nedaplatin Combined with Chemotherapy for Advanced Non-small Cell Lung Cancer: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content